Saturday 17 October 2026
Export PRGO’s income statement to Excel — free account
Perrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
16.63
0.15
+0.91%
Follow PRGO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.35 | 0.36 | 0.45 | 0.72 | |
P/FCF ratio |
11.35 | 12.88 | 12.57 | 10.88 | |
P/Operating CF |
17.50 | (13.11) | 10.99 | 59.66 | |
P/B ratio |
0.57 | 0.60 | 0.66 | 0.69 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.05 | 1.14 | 1.18 | 1.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 10.07 | |
EV/Operating CF |
22.13 | 25.16 | 21.12 | 16.76 | |
EV/FCF |
34.10 | 41.18 | 32.83 | 22.20 | |
Quick Ratio |
1.05 | 1.06 | 1.13 | 0.94 | |
Current Ratio |
2.32 | 2.72 | 2.76 | 2.51 | |
Net Debt/EBITDA |
23.87 | (11.42) | (2.59) | 20.04 | |
Debt/Assets |
43.30% | 45.50% | 42.65% | 36.14% | |
Debt/Equity |
1.31 | 1.45 | 1.24 | 0.82 | |
Asset Turnover |
0.47 | 0.47 | 0.47 | 0.40 | |
Operating CF/Net income |
1.11 | 0.29 | (0.12) | 6.89 | |
Capex/Depreciation |
(0.15) | (0.14) | (0.28) | (0.21) | |
Interest Coverage |
0.61 | (9.12) | (29.73) | 1.79 | |
Research and Development Expense of Revenue |
2.32% | 2.54% | 1.96% | 2.39% | |
Selling, General and Administrative Expense of Revenue |
24.56% | 27.58% | 23.05% | 23.55% | |
Intangible Assets out of Total Assets |
0.51 | 0.50 | 0.52 | 0.57 | |
Share Based Compensation of Revenue |
0.66% | 1.49% | 1.17% | 1.27% | |
Graham Net Nets |
(1.83) | (1.86) | (1.45) | (0.89) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(120.31%) | (121.97%) | (73.85%) | (1.71%) | |
Free Cash Flow Yield |
8.81% | 7.77% | 7.96% | 9.19% | |
Revenue per Share |
7.35 | 6.99 | 8.01 | 7.53 | |
Operating CF per Share |
0.59 | (0.82) | 1.27 | 0.37 | |
Capex per Share |
(0.10) | (0.09) | (0.18) | (0.13) | |
Free Cash Flow per Share |
0.49 | (0.91) | 1.09 | 0.24 | |
Cash per Share |
2.87 | 2.58 | 3.84 | 3.12 | |
Shareholders Equity per Share |
18.09 | 18.02 | 21.19 | 32.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.09 | 18.02 | 21.19 | 32.10 | |
Free Cash Flow |
68.30 | (126.00) | 151.00 | 33.00 | |
Working Capital |
1,396.90 | 1,714.80 | 1,784.50 | 1,733.90 | |
Capital Expenditures |
(14.30) | (12.40) | (24.40) | (18.70) | |
Net Current Asset Value |
(2,642.00) | (2,772.10) | (2,802.30) | (2,758.30) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 22.56 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 11.05 | |
| Other line items | |||||
Average Receivables |
694.05 | 706.95 | 627.55 | 715.15 | |
Average Payables |
444.70 | 468.55 | 484.85 | 464.10 | |
Average Inventory |
1,140.00 | 1,138.20 | 1,115.40 | 1,180.40 | |
Average Assets |
8,851.80 | 8,871.55 | 9,091.45 | 10,643.60 | |
Average Common Equity |
3,494.05 | 3,431.40 | 3,627.45 | 4,506.25 |
Columns are period end dates